ArticlePPAR research2007
Nuclear Receptors in Regulation of Mouse ES Cell Pluripotency and Differentiation.
Article in PPAR research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Epiblast lumenogenesis is not a mammalian-specific trait.Nature communications · 2026Article
- International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.Pharmacological reviews · 2023Review
- Nr6a1 controls Hox expression dynamics and is a master regulator of vertebrate trunk development.Nature communications · 2022Article
- Regulation of Oct4 in stem cells and neural crest cells.Birth defects research · 2022Review
- RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells.Haematologica · 2022Article
- The Schistosoma mansoni nuclear receptor FTZ-F1 maintains esophageal gland function via transcriptional regulation of meg-8.3.PLoS pathogens · 2021Article
- Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disorders.Nature communications · 2021Article
- Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.Expert opinion on therapeutic targets · 2021Review
- The emerging role of estrogen related receptorα in complications of non-small cell lung cancers.Oncology letters · 2021Review
- Etiopathogenesis, Challenges and Remedies Associated With Female Genital Tuberculosis: Potential Role of Nuclear Receptors.Frontiers in immunology · 2020Review
- Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Peroxisome Proliferator-Activated Receptor α Agonist and Its Target Nanog Cooperate to Induce Pluripotency.Journal of clinical medicine · 2018Article
- Nuclear receptors in neural stem/progenitor cell homeostasis.Cellular and molecular life sciences : CMLS · 2017Review
- Positive expression of NR6A1/CT150 as a predictor of biochemical recurrence-free survival in prostate cancer patients.Oncotarget · 2017Article
- CBP/Catenin antagonists: Targeting LSCs' Achilles heel.Experimental hematology · 2017Review
- A Structural Investigation into Oct4 Regulation by Orphan Nuclear Receptors, Germ Cell Nuclear Factor (GCNF), and Liver Receptor Homolog-1 (LRH-1).Journal of molecular biology · 2016Article
- Pathways of retinoid synthesis in mouse macrophages and bone marrow cells.Journal of leukocyte biology · 2016Article
- Kat3 coactivators in somatic stem cells and cancer stem cells: biological roles, evolution, and pharmacologic manipulation.Cell biology and toxicology · 2016Review
- The orphan nuclear receptors at their 25-year reunion.Journal of molecular endocrinology · 2013Review
- Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.Journal of cellular physiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem (ES) cells have great therapeutic potential because they are capable of indefinite self-renewal and have the potential to differentiate into over 200 different cell types that compose the human body. The switch from the pluripotent phenotype to a differentiated cell involves many complex signaling pathways including those involving LIF/Stat3 and the transcription factors Sox2, Nanog and Oct-4. Many nuclear receptors play an important role in the maintenance of pluripotence (ERRbeta, SF-1, LRH-1, DAX-1) repression of the ES cell phenotype (RAR, RXR, GCNF) and also the differentiation of ES cells (PPARgamma). Here we review the roles of the nuclear receptors involved in regulating these important processes in ES cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.